AVEO PHARMACEUTICALS INC (AVEO) Fundamental Analysis & Valuation

NASDAQ:AVEO • US0535883070

Current stock price

15 USD
0 (0%)
At close:
15 USD
0 (0%)
After Hours:

This AVEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AVEO Profitability Analysis

1.1 Basic Checks

  • AVEO had negative earnings in the past year.
  • AVEO had a negative operating cash flow in the past year.
AVEO Yearly Net Income VS EBIT VS OCF VS FCFAVEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M

1.2 Ratios

  • AVEO has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVEO Yearly ROA, ROE, ROICAVEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 500 1K

1.3 Margins

  • With an excellent Gross Margin value of 87.81%, AVEO belongs to the best of the industry, outperforming 91.08% of the companies in the same industry.
  • AVEO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVEO Yearly Profit, Operating, Gross MarginsAVEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. AVEO Health Analysis

2.1 Basic Checks

  • AVEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AVEO has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for AVEO is higher compared to a year ago.
AVEO Yearly Shares OutstandingAVEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
AVEO Yearly Total Debt VS Total AssetsAVEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -4.48, we must say that AVEO is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of AVEO (-4.48) is worse than 68.86% of its industry peers.
  • A Debt/Equity ratio of 0.94 indicates that AVEO is somewhat dependend on debt financing.
  • AVEO has a Debt to Equity ratio of 0.94. This is amonst the worse of the industry: AVEO underperforms 82.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Altman-Z -4.48
ROIC/WACCN/A
WACC9.35%
AVEO Yearly LT Debt VS Equity VS FCFAVEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 2.37 indicates that AVEO has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.37, AVEO is doing worse than 78.87% of the companies in the same industry.
  • AVEO has a Quick Ratio of 2.35. This indicates that AVEO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of AVEO (2.35) is worse than 77.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.35
AVEO Yearly Current Assets VS Current LiabilitesAVEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. AVEO Growth Analysis

3.1 Past

  • AVEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
  • The Revenue has grown by 269.46% in the past year. This is a very strong growth!
  • Measured over the past years, AVEO shows a very strong growth in Revenue. The Revenue has been growing by 76.06% on average per year.
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%

3.2 Future

  • Based on estimates for the next years, AVEO will show a very strong growth in Earnings Per Share. The EPS will grow by 40.39% on average per year.
  • Based on estimates for the next years, AVEO will show a very strong growth in Revenue. The Revenue will grow by 75.28% on average per year.
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
AVEO Yearly Revenue VS EstimatesAVEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AVEO Yearly EPS VS EstimatesAVEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

3

4. AVEO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AVEO. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 27.40, which means the current valuation is very expensive for AVEO.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AVEO indicates a rather cheap valuation: AVEO is cheaper than 96.09% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.04. AVEO is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 27.4
AVEO Price Earnings VS Forward Price EarningsAVEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVEO Per share dataAVEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • AVEO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as AVEO's earnings are expected to grow with 40.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.26%
EPS Next 3Y40.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVEO Dividend Analysis

5.1 Amount

  • AVEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AVEO Fundamentals: All Metrics, Ratios and Statistics

AVEO PHARMACEUTICALS INC

NASDAQ:AVEO (1/19/2023, 8:09:51 PM)

After market: 15 0 (0%)

15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-13
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.7%
Ins Owner Change0%
Market Cap521.45M
Revenue(TTM)94.32M
Net Income(TTM)-29.04M
Analysts50
Price Target15.3 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.92%
Min EPS beat(2)15.97%
Max EPS beat(2)49.87%
EPS beat(4)3
Avg EPS beat(4)18.91%
Min EPS beat(4)-18.6%
Max EPS beat(4)49.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-1.32%
Min Revenue beat(4)-3.54%
Max Revenue beat(4)1.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)56.59%
EPS NY rev (1m)0%
EPS NY rev (3m)10.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.4
P/S 5.53
P/FCF N/A
P/OCF N/A
P/B 18.08
P/tB 18.08
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)0.55
Fwd EY3.65%
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS2.71
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.81%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.35
Altman-Z -4.48
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A
EBIT growth 1Y56.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.21%
OCF growth 3YN/A
OCF growth 5YN/A

AVEO PHARMACEUTICALS INC / AVEO Fundamental Analysis FAQ

What is the fundamental rating for AVEO stock?

ChartMill assigns a fundamental rating of 3 / 10 to AVEO.


What is the valuation status for AVEO stock?

ChartMill assigns a valuation rating of 3 / 10 to AVEO PHARMACEUTICALS INC (AVEO). This can be considered as Overvalued.


How profitable is AVEO PHARMACEUTICALS INC (AVEO) stock?

AVEO PHARMACEUTICALS INC (AVEO) has a profitability rating of 1 / 10.


What is the expected EPS growth for AVEO PHARMACEUTICALS INC (AVEO) stock?

The Earnings per Share (EPS) of AVEO PHARMACEUTICALS INC (AVEO) is expected to grow by 59.87% in the next year.